Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in locally advanced cervical cancer (ATEZOLACC). This evidence concerns the gene CD274 and cervical carcinoma.